CN111991429B - Application of lactobacillus reuteri in preparation of products for resisting oral bacterial infection - Google Patents
Application of lactobacillus reuteri in preparation of products for resisting oral bacterial infection Download PDFInfo
- Publication number
- CN111991429B CN111991429B CN202010836924.0A CN202010836924A CN111991429B CN 111991429 B CN111991429 B CN 111991429B CN 202010836924 A CN202010836924 A CN 202010836924A CN 111991429 B CN111991429 B CN 111991429B
- Authority
- CN
- China
- Prior art keywords
- oral
- lactobacillus reuteri
- dsm17648
- preparation
- bacterial infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Abstract
The invention discloses application of lactobacillus reuteri in preparation of products for resisting oral bacterial infection, and the inactivated lactobacillus reuteri DSM17648 is taken as a unique probiotic active component, so that various pathogenic bacteria in oral cavities can be effectively resisted, and a series of oral problems such as halitosis, oral ulcer, chronic pharyngitis, periodontitis and the like are solved. An article of manufacture for combating bacterial infections of the oral cavity is also disclosed.
Description
Technical Field
The invention relates to the technical field of pharmaceutical chemicals and medical instruments, in particular to application of lactobacillus reuteri in preparing products for resisting oral bacterial infection.
Background
Oral bacterial infection easily causes a series of oral problems such as halitosis, canker sore, chronic pharyngitis, periodontitis and the like, and oral pathogenic bacteria are various and comprise helicobacter pylori, prevotella intermedia, porphyromonas pulposus, streptococcus mutans and the like, different pathogenic bacteria can cause different oral problems, and the pathogenic bacteria of the same oral problem can also be different.
In the case of periodontitis, studies have shown that helicobacter pylori, prevotella intermedia and the like are closely related to the occurrence of periodontitis. Helicobacter Pylori (HP) is a bacterium parasitizing in the stomach, and can cause inflammation when being adhered to gastric mucosa and intercellular spaces, helicobacter pylori is infected in the stomach generally, helicobacter pylori also exists in the oral cavity, oral cavity helicobacter pylori can cause a series of oral problems such as halitosis, oral ulcer, chronic pharyngitis, periodontitis and the like, and the problems seriously affect the life quality of people.
Probiotics are useful as microbial agents that, when ingested in sufficient quantities, can exert beneficial effects on human health. Currently common oral probiotics are mainly lactobacillus and bifidobacterium, and different types of probiotics may have different antibacterial effects. In view of the specificity of the antibacterial action of probiotics, the existing microbial preparations with probiotics as active ingredients are usually used to combat certain or certain specific pathogenic bacteria. For example, it has been shown that Lactobacillus reuteri can be used for preventing or treating diseases caused by helicobacter pylori infection, especially gastrointestinal diseases such as gastric ulcer, etc., and after entering the gastrointestinal tract of human body, its special structure will quickly adhere and wrap helicobacter pylori, so that it is separated from gastric mucosa and eliminated with it.
However, the pathogenic bacteria in the oral cavity are various, a microbial preparation capable of effectively resisting various bacterial infections is not available at present, and the problems of great difficulty in radical treatment and easy recurrence of oral bacterial infection diseases are difficult to fundamentally solve.
Disclosure of Invention
The invention aims to at least solve one of the technical problems in the prior art, and provides the lactobacillus reuteri DSM17648 which can effectively resist various pathogenic bacteria in the oral cavity, can be applied to preparing products for resisting oral bacterial infection and solves a series of oral problems such as halitosis, oral ulcer, chronic pharyngitis, periodontitis and the like.
According to some embodiments of the present invention there is provided the use of lactobacillus reuteri in the manufacture of a preparation against oral bacterial infection with inactivated lactobacillus reuteri DSM17648 as the sole probiotic active ingredient.
According to some embodiments of the present invention there is also provided an anti-oral bacterial infection preparation comprising inactivated lactobacillus reuteri DSM17648 as the sole probiotic active ingredient.
In the above examples, the amount of Lactobacillus reuteri DSM17648 is exemplified by 2 to 20 wt% based on utility and cost considerations. At least one carrier may also be included.
In some embodiments, the oral bacterial infection resistant article is selected from the group consisting of household chemical products and medical devices.
One or more embodiments of the invention have at least the following beneficial effects:
the inventor finds that the lactobacillus reuteri DSM17648 shows good antibacterial activity on various common oral pathogenic bacteria such as helicobacter pylori, porphyromonas pulposus, prevotella intermedia, streptococcus mutans and the like, and the antibacterial effect is obviously better than that of other types of probiotics and other strains belonging to the lactobacillus reuteri. Can remarkably prevent, resist or eliminate common pathogenic bacteria in the oral cavity, and better solve a series of oral problems such as halitosis, canker sore, chronic pharyngitis, periodontitis and the like.
Detailed Description
In order to make the objects, technical solutions and advantages of the present application more apparent, the following detailed description is given with reference to specific embodiments. The embodiments described herein are only some of the embodiments of the present application and should not be construed as limiting the scope of the present application.
The embodiment of the invention provides application of inactivated lactobacillus reuteri DSM17648 in preparing an anti-oral bacterial infection preparation. Experiments show that the lactobacillus reuteri DSM17648 has better antibacterial activity on various common oral pathogenic bacteria such as helicobacter pylori, porphyromonas pulposus, prevotella intermedia, streptococcus mutans and the like, and the antibacterial effect is obviously better than that of other types of probiotics and other strains belonging to the lactobacillus reuteri.
Due to the excellent characteristics, the inactivated lactobacillus reuteri DSM17648 is used as the only probiotic active ingredient for preparing the product for resisting oral bacterial infection, and a series of oral problems such as halitosis, oral ulcer, chronic pharyngitis, periodontitis and the like can be better solved.
Embodiments of the present invention also provide an anti-oral bacterial infection preparation comprising inactivated lactobacillus reuteri DSM17648 as the sole probiotic active ingredient.
In practical application, more than one carrier can be added for shaping, and the type and content of the carrier can be selected according to different products, and the corresponding carrier and content thereof are well known in the art.
For example, the product for resisting oral bacterial infection can be daily chemical products and medical appliances, wherein the daily chemical products include but are not limited to toothpaste, tooth powder, mouthwash and the like, and the medical appliances include but are not limited to oral spray, oral effervescent tablets, chewable tablets, oral dressings and the like.
The formulation and preparation method of the product can also refer to the prior art, and lactobacillus reuteri DSM17648 is additionally added as the active component of the probiotics.
The use of Lactobacillus reuteri DSM17648 is described below with a part of the preparation as an example. It is noted that the amount of lactobacillus reuteri DSM17648 used in the present invention is not particularly limited, and is exemplified by 2 to 20 wt% based on utility and cost considerations. For comparison, examples 1-6 are given by way of example of 5 wt%.
In the following examples and comparative examples, all probiotics used were killed bacteria.
Example 1: oral spray containing Lactobacillus reuteri DSM17648
The formula comprises the following components in parts by weight:
lactobacillus reuteri DSM 176485 parts
Physiological saline 45 parts
50 parts of purified water
The preparation method comprises the following steps: mixing Lactobacillus reuteri DSM17648, physiological saline and purified water.
Example 2: oral effervescent tablet containing Lactobacillus reuteri DSM17648
The formula comprises the following components in parts by weight:
the preparation method comprises the following steps: weighing all the materials according to the formula amount, uniformly blending, and tabletting by using a tabletting machine to obtain the tablet.
Example 3: chewable tablet containing Lactobacillus reuteri DSM17648
The formula comprises the following components in parts by weight:
the preparation method comprises the following steps: pulverizing Mentholum, sieving the rest materials with 40 mesh sieve, mixing the pulverized Mentholum with sucralose, lactose, polyvinylpyrrolidone, sodium laurylsulfate, edible essence, and Lactobacillus reuteri DSM17648 powder, adding the rest materials into the above mixture, mixing, and tabletting.
Example 4: mouthwash containing lactobacillus reuteri DSM17648
The formula comprises the following components in parts by weight:
the preparation method comprises the following steps: dissolving beta-cyclodextrin, fructo-oligosaccharide and tween 80 with part of purified water, adding sodium benzoate to obtain a mixture, adding other materials and the rest purified water, and stirring.
Example 5: toothpaste containing Lactobacillus reuteri DSM17648
The formula comprises the following components in parts by weight:
example 6: pure lactobacillus reuteri DSM17648
The formula comprises the following components in parts by weight:
lactobacillus reuteri DSM 176485 parts
Purified water 95 parts
The preparation method comprises the following steps: mixing Lactobacillus reuteri DSM17648 and purified water.
Comparative example 1
With reference to example 5, the difference is that the Lactobacillus reuteri DSM17648 is replaced by an equal amount of Lactobacillus reuteri CICC 6188.
Comparative example 2
The formula comprises the following components in parts by weight:
comparative example 3
The formula comprises the following components in parts by weight:
test example 1
Used to test the bacteriostatic activity of oral H.pylori in examples 1-6 and comparative examples 1-3.
The detection method comprises the following steps: taking 10 parts of helicobacter pylori culture medium, dividing each part into 2 groups, and adding the samples of the above examples 1-6 and comparative examples 1-3 into one group of each culture medium to serve as a test group; the other group is not added with any sample and is used as a control group; then inoculating helicobacter pylori respectively, culturing in the same condition, counting the colony number of each culture medium, and calculating the bacteriostasis rate.
The bacteriostasis rate is (number of colonies in a control group-number of colonies in a test group)/number of colonies in a control group is 100%
Results of bacteriostatic rate are shown in table 1:
TABLE 1
As can be seen from the above table, examples 1 to 6 all can effectively inhibit oral helicobacter pylori, and the effect of inhibiting oral helicobacter pylori is superior to other probiotics of comparative example 1 and comparative example 2. Comparative example 3 lactobacillus reuteri DSM17648 was used in combination with other probiotics with a bacteriostatic effect comparable to that of lactobacillus reuteri DSM17648 alone.
Test example 2
Examples 1-6 and comparative examples 1-3 were used to test the bacteriostatic activity of other oral pathogens, including Porphyromonas pulposus, Prevotella intermedia, and Streptococcus mutans.
Suspending Porphyromonas pulposus and Prevotella intermedia in brain heart infusion broth, culturing at 37 deg.C for 48h, suspending Streptococcus mutans in trypticase soybean broth, culturing at 37 deg.C for 48h, centrifuging at 3000r/min for 10min, and discarding supernatant to obtain bacterial liquid. The experiment was divided into 10 groups, namely, physiological saline solutions of examples 1 to 6, comparative examples 1 to 3 and control groups, and the samples of examples 1 to 6 and comparative examples 1 to 3 were prepared as aqueous solutions having an equivalent cell concentration. Circular filter paper sheets of 6mm in diameter sterilized at 121 ℃ for 15min were soaked in 1ml each of the aqueous solutions of examples and comparative examples and physiological saline, 5 filter paper sheets for each solution, and after 5min, they were taken out and drained. Respectively dipping prepared dental pulp porphyromonas, prevotella intermedia and streptococcus mutans bacterial liquids by using a sterile cotton swab, lightly and parallelly marking lines on a blood agar plate in 4 directions in a cross way, and uniformly coating the lines. Filter paper sheets soaked with different sample solutions were placed on the surface of inoculated bacterial agar plates, respectively. Each sample was repeated 6 times for each bacterium. Each plate was incubated in an incubator at 37 ℃ for 48 hours, and the diameter of the bacteriostatic ring on each plate was measured with a vernier caliper.
Results of bacteriostatic rate are shown in table 2:
TABLE 2
| Porphyromonas pulposus | Prevotella intermedia | Streptococcus mutans | |
| Example 1 | 25.4±0.7 | 21.2±0.8 | 15.5±0.9 |
| Example 2 | 26.4±0.6 | 21.4±1.3 | 14.9±1.0 |
| Example 3 | 23.5±0.8 | 22.5±0.7 | 13.6±0.9 |
| Example 4 | 25.2±0.9 | 20.4±1.3 | 15.3±0.9 |
| Example 5 | 27.2±1.4 | 19.1±1.5 | 16.2±1.2 |
| Example 6 | 25.1±1.7 | 19.2±1.1 | 14.6±1.7 |
| Comparative example 1 | 16.5±1.2 | 15.6±1.5 | 12.2±1.3 |
| Comparative example 2 | 20.2±1.4 | 8.8±1.4 | 6.6±1.3 |
| Comparative example 3 | 25.3±1.8 | 19.9±1.0 | 14.7±1.2 |
| Physiological saline | No bacteriostatic ring | No bacteriostatic ring | No bacteriostatic ring |
The results show that examples 1 to 6 all have good inhibitory effects on Porphyromonas pulposus, Prevotella intermedia and Streptococcus mutans, which cause oral diseases.
From the above results, it can be seen that the lactobacillus reuteri DSM17648 as the active component of the probiotic has a significant advantage in inhibiting various oral pathogenic bacteria, compared to other probiotics.
Claims (8)
1. Use of lactobacillus reuteri for the preparation of a preparation against oral bacterial infections, characterized in that inactivated lactobacillus reuteri DSM17648 is used as the sole probiotic active ingredient;
the product for resisting oral bacterial infection is a product for inhibiting Porphyromonas pulposus, Prevotella intermedia and Streptococcus mutans.
2. Use according to claim 1, wherein the lactobacillus reuteri DSM17648 is used in an amount of 2-20 wt%.
3. An anti-oral bacterial preparation comprising inactivated lactobacillus reuteri DSM17648 as the sole probiotic active ingredient;
the product for resisting oral bacterial infection is a product for inhibiting Porphyromonas pulposus, Prevotella intermedia and Streptococcus mutans.
4. The preparation for resisting oral bacterial infection according to claim 3, wherein the amount of Lactobacillus reuteri DSM17648 is 2-20 wt%.
5. The oral bacterial infection-combating article according to claim 3 or 4, further comprising at least one carrier.
6. An article according to claim 3 or 4, wherein the article is selected from the group consisting of oral spray, oral effervescent tablet, chewable tablet, oral dressing.
7. An article according to claim 3 or 4, wherein the article is further selected from a daily chemical product.
8. The article of claim 7, wherein the daily chemical product is selected from the group consisting of toothpaste, tooth powder, and mouthwash.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010836924.0A CN111991429B (en) | 2020-08-19 | 2020-08-19 | Application of lactobacillus reuteri in preparation of products for resisting oral bacterial infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010836924.0A CN111991429B (en) | 2020-08-19 | 2020-08-19 | Application of lactobacillus reuteri in preparation of products for resisting oral bacterial infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111991429A CN111991429A (en) | 2020-11-27 |
| CN111991429B true CN111991429B (en) | 2022-08-26 |
Family
ID=73472687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010836924.0A Active CN111991429B (en) | 2020-08-19 | 2020-08-19 | Application of lactobacillus reuteri in preparation of products for resisting oral bacterial infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111991429B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112430553A (en) * | 2020-11-25 | 2021-03-02 | 山东向日葵生物工程有限公司 | Lactobacillus reuteri SF-L-25 with helicobacter pylori inhibiting function and application thereof |
| CN113337431B (en) * | 2021-06-04 | 2022-08-05 | 青岛诺森生物技术有限责任公司 | Lactobacillus reuteri NSL0501 for inhibiting helicobacter pylori as well as biological agent and application thereof |
| CN113425831A (en) * | 2021-07-13 | 2021-09-24 | 镇江市天益生物科技有限公司 | Probiotic composition for treating oral ulcer and preparation method and application thereof |
| CN113384516A (en) * | 2021-07-15 | 2021-09-14 | 中盐工程技术研究院有限公司 | Novel gargle salt and preparation method thereof |
| CN115109713B (en) * | 2022-03-08 | 2023-10-31 | 均瑶润盈生物科技(上海)有限公司 | Probiotics and biological agents for alleviating traumatic oral lesions |
| CN116622570B (en) * | 2023-05-22 | 2023-11-03 | 微康益生菌(苏州)股份有限公司 | Lactobacillus reuteri LR08, and application, product and method thereof in preparation of medicines for preventing and treating vaginitis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005062731A1 (en) * | 2005-12-22 | 2007-06-28 | Organobalance Gmbh | New Lactobacillus strains and their use |
| CN105087434A (en) * | 2015-08-13 | 2015-11-25 | 吴前进 | High-producing 3-hydroxypropionaldehyde strain and application thereof to prevention and treatment of oral cavity infection of mammals |
-
2020
- 2020-08-19 CN CN202010836924.0A patent/CN111991429B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111991429A (en) | 2020-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111991429B (en) | Application of lactobacillus reuteri in preparation of products for resisting oral bacterial infection | |
| US10449222B2 (en) | Method for preventing and/or treating infections, colonisations, or illnesses related to Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pyogenes, Enterococcus faecium, Enterobacter cloacae, Proteus mirabilis, Bacteroides fragilis, Staphylococcus epidermidis, Propionibacterium acnes, Candida albicans and/or Malassezia furfur | |
| CN108048347A (en) | Lactobacillus rhamnosus, lactobacillus rhamnosus preparation and application thereof | |
| RU2004130876A (en) | STRAINS LACTOBACILLUS | |
| CN114504109B (en) | Composition containing bifidobacterium lactis and breast milk oligosaccharide and application thereof | |
| CN103409334B (en) | Inhibit the Bacillus acidi lactici and application thereof of vaginitis pathogen | |
| CN113577218A (en) | Inactivated probiotic traditional Chinese medicine composition for inhibiting helicobacter pylori and preparation method and application thereof | |
| KR101000364B1 (en) | Double-coating methods for enhancing viability | |
| CN111084831A (en) | Bacteriostatic composition for inhibiting vaginal pathogenic bacteria and application thereof | |
| CN108542954A (en) | A kind of Traditional Chinese medicine gel composition of inhibitory anti-virus | |
| CN115119940A (en) | Application of Lactobacillus acidophilus LA85 and Bifidobacterium lactis BLA80 in inhibiting helicobacter pylori | |
| KR20180056896A (en) | Microbial preparation(powder) for formula-fed babies produced with Lactobacillus gasseri J12P4 and Staphylococcus epidermidis J4P1 isolated from Korean breast milk | |
| CN116024128B (en) | Streptococcus thermophilus strain P0012, and probiotic composition for oral health care prepared from same and application of probiotic composition | |
| KR102342160B1 (en) | Composition comprising taxifolin for inhibiting the formation of biofilm | |
| CN114504108B (en) | Composition containing lactobacillus paracasei and breast milk oligosaccharide and application thereof | |
| CN115094001B (en) | Leuconostoc mesenteroides and application thereof in preparation of helicobacter pylori inhibiting drugs | |
| CN116731913B (en) | Application of lactobacillus plantarum in preparation of helicobacter pylori resistant products | |
| CN115581272B (en) | Application of stevioside and probiotics in preparation of helicobacter pylori inhibiting products | |
| CN114504107B (en) | Composition containing lactobacillus rhamnosus and breast milk oligosaccharide and application thereof | |
| CN113546100B (en) | Application of pachyrhizus extract in preparation of antibacterial product | |
| KR102439760B1 (en) | Composition for the prevention and/or treatment of upper respiratory virus infections | |
| KR102441377B1 (en) | Composition comprising pectolinarin for inhibiting the formation of biofilm | |
| Frehatsari et al. | Antibacterial Activity of Probiotic Milk Lactobacillus paracasei and Randu Honey (Ceiba pentandra) Against Streptococcus mutans | |
| CN114452379A (en) | Probiotic composition containing active lactic acid and preparation method thereof | |
| CN117679551A (en) | Traditional Chinese medicine chip with health care function, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Liu Rui Inventor after: Zou Hui Inventor after: Tan Jianbing Inventor after: Yang Peng Inventor after: Li Zhen Inventor before: Zou Hui Inventor before: Liu Rui Inventor before: Tan Jianbing Inventor before: Yang Peng Inventor before: Li Zhen |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |